Quantib gains FDA clearance for AI solution that helps radiologists read MRI brain scans

Quantib, a medical technology company based out of Rotterdam, the Netherlands, has received FDA clearance for its Quantib Neurodegenerative (ND) solution.

Quantib ND uses machine learning for the automated measurement of brain atrophy and detection of white matter hyperintensities in MRI scans of the brain. Users send a scan to the workstation and pre-processing begins automatically.

In addition, Quantib ND can be used to track changes to the brain over time. The solution also offers detailed reports, which can be downloaded or uploaded to a facility’s PACS.

“This is an important achievement,” Arthur Post Uiterweer, CEO of Quantib, said in a prepared statement. “We are very proud to offer physicians an extensive software package for quantitative measurements of neurological changes that can be related to dementia and MS.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.

And it can do so with almost 100% accuracy as a first reader, according to a new large-scale analysis.

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.